Interested in submitting to this journal? We recommend that you review the About the Journal page for the journal's section policies, as well as the Author Guidelines. Authors need to register with the journal prior to submitting or, if already registered, can simply log in and begin the five-step process.
The journal of Artificial Intelligence In Oncology features following kinds of publications:
Original Research Papers: Laboratory/clinic/computer-based theoretical and/or methodological papers;
Case reports: Clinical application of AI in cancer patients;
Reviews: Comprehensive overview of AI and oncology;
Perspectives: Experts insights in the field of AI and oncology;
Editorials: Editors may publish editorials;
Letters-to-the-editor: Short letters from readers that discuss a relevant issue related with the topics of the journal or a specific paper published in Artificial Intelligence In Oncology.
Erratum: Specific corrections of results that papers published in Artificial Intelligence In Oncology.
No Permission Required
Artificial Intelligence in Oncology applies the Creative Commons Attribution 3.0 License to all works we publish (for details: human-readable summary and the full license legal code). Under the agreement, authors will retain ownership of the copyright for their article, but authors allow anyone to download, reprint, reuse, modify, distribute, and/or copy articles in Artificial Intelligence in Oncology , so long as the original authors and the article are cited.
The publication ethics and malpractice guidelinces for Artificial Intelligence in Oncology are devloped from Committee on Publication Ethics (COPE, https://publicationethics.org/resources/guidelines). Authors listed as co-authors should have made substantial contribution in the 1) design and conception of the manuscript; 2) drafting of the manuscript and revisions; 3) final approval and review of the accepted manuscript. The corresponding author should provide contact information for each authors listed as co-authors in the manuscript. The corresponding author should ensure all the listed co-authors agree with the authorship and all the conflicts of interests are declared if any. Any malpractice and manipulation of data presented in the manuscript and the supplemental section will be executed based on COPE. Contact firstname.lastname@example.org for changes of authorship after the manuscript has been submitted.
Authors agree that when a manuscript is submitted for consideration of publication in Artificial Intelligence in Oncology, neither the original manuscript nor any similar manuscript containing the majority or part of the content submited is under consideration, press, publication in other journal, or it has been reported elsewhere. The corresponding author is responsible in attest that the submitted manuscript has no prior or subsequent publications.
All the manuscripts accepted for pulication by Artificial Intelligence in Oncology have undergone peer-review by at least 2 experts in the field. The Assocate Editors will select the experts in the field as the reviewers once the Senior Editors agree submitted manuscript is relevant to the scope of the journal. After receiving reviews (at least two), Senior Editors and/or the Editor-in-Chief make decisions based on the data presented in the manuscript and the comments made by the reviewers. The paper will be either rejected or sent back to the corresponding author for revisions. Typically 3-5 months will be allowed for the authors to finish the revisions and draft the corresponding letter (rebuttal). After revision, the Editors send the revised version of the paper to the reviewers for their comments and evaluations. Final decisions will be made based on the reviewers' additional comments. Editors must make a final decision no later than 1 week after the reviewers submitted their additional comments. The contents of manuscripts are considered as privileged. All Editors and reviewers involved in the processing of the manuscript are required to maintain the confidentiality concerning all manuscripts and its contents. Identities of reviewers will not be revealed to authors to ensure the reviewers' decisions are based solely on the quality of the manuscript.
All manuscripts should be written in proper English. The journal AIO does not provide editing for spelling and grammar. The main manuscript text file should be in .doc format and start with a title page (with title, authors, corresponding author contact information—address, fax, and email, three to five key words).
Original research articles and short reports should follow the IRDAM format (Introduction, Results, Discussion, and Materials and Methods). Acknowledgments, References, Tables, Figure Legends and Figure Legends for the supplemntal information shall follow the body of the text. The supplemental text supporting the main text should be submitted as a seperate file following the format of RF (Results, References). The Figures for both the main text and the supplemntal information should be submitted seperately with clearly labelled numbering for each figure. Supporting equations, programs, algorithms and videos supporting the manuscript should also be submitted seperately.
Reviews should focus on the most up-to-date development and application of AI in the field of oncology. The text not exceed 4,500 words in length (from Introduction to Discussion/Conclusions) and should be limited to a maximum of 4 tables/figures in total. No limit on the number of references cited.
Case reports will focus primarily on the application of AI concepts and algorithm in treating cancer patients. The text should not excced 1,500 words in length with a maximum of 3 tables and figures in total. The number of references should not exceed 25. No abstract is need. The corresponding author is responsible in providing patients' agreement forms.
The journal does not require a specific format for references. The style of the references will be edited by the Production team upon article acceptance. However, the following format of reference is recommended:
The list of references, immediately following the text, should be numbered consecutively based on the first time the reference is mentioned in the manuscript. Before submission of the manuscript, authors should make sure the accuracy of all references. All numbered reference in the manuscript should use [ ] not ( ). For example: "based on the previously reported study ".
Please use the following style for references in all types of papers to be submitted to AIO:
Artificial Intelligence in Oncology strongly recomends authors to use an automated reference manager such as Thomson Reuters Endnote. Please email email@example.com to download the endnote template of AIO.
Following the reference, authors should provide a conflict of interest statement. Corresponding authors should ensure all co-authors to confirm agreement with the final statement. A conflict of interest is defined as a situation in which a source of funding, or any financial and personal relationships that might bias the authors’ work.
AIO is a currently providing FREE online-only publication service for original research articles. The Editorial board believes that the free online-only publication policy will faciliate the communication between scholars with or without funding. Invited reviews, case reports and editorials are also free to publish in AIO. The printed version of published articles are available upon request with a cost of 150 $. Payments can be made with either credit cards or Paypal (see below). The receipts will be forwarded to the listed corresponding author upon print publication of the paper. Please note the payment is nonrefundable.